PPHM up 9%. This must annoy those who say that when PPHM presents data it is "cherry picked" and when they do not present data it is because it is "bad". Actually the complete data set needs to be studied...and shared with potential partners. The success of this trial is determined by what they learned from it. Certainly they learned about safety and tolerability. Probably they learned about dosing. And certainly they learned about duration of treatment needed in this particular combination. Ultimately the value will only be determined by future partnering or by further internal development after the many phase II cancer trials data are in.
News 
Market Data 
Discover 
